Famitinib (BioDeep_00000838056)
代谢物信息卡片
化学式: C23H27FN4O2 (410.2117934)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)C=C3C4=C(C=CC(=C4)F)NC3=O)C
InChI: InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 16662431
- DrugBank: DB11741
- ChEMBL: CHEMBL1278146
- CAS: 1044040-56-3
- CAS: 945380-27-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Yuan-Yuan Qu, Hai-Liang Zhang, Hongqian Guo, Hong Luo, Qing Zou, Nianzeng Xing, Shujie Xia, Zhongquan Sun, Xuepei Zhang, Chaohong He, Jinling Cai, Xiao Zhang, Quanren Wang, Ding-Wei Ye. Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 11; 27(21):5838-5846. doi:
10.1158/1078-0432.ccr-21-1698
. [PMID: 34400414] - Timothy Thomas. Camrelizumab plus famitinib to treat RCC.
Nature reviews. Urology.
2021 10; 18(10):576. doi:
10.1038/s41585-021-00517-6
. [PMID: 34453154] - Shiyi Liu, Hua Wei, Xiaobin Gong, Tianyi Xia, Jianxiu Zhai, Wansheng Chen, Xia Tao. LC-MS/MS method for simultaneous determination of famitinib and its major metabolites in human plasma.
Bioanalysis.
2018 Jun; 10(11):791-801. doi:
10.4155/bio-2017-0258
. [PMID: 29863414] - Jun Cao, Jian Zhang, Zhonghua Wang, Biyun Wang, Fangfang Lv, Leiping Wang, Xichun Hu. Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Cancer chemotherapy and pharmacology.
2014 Aug; 74(2):389-98. doi:
10.1007/s00280-014-2505-x
. [PMID: 24939214] - Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Cancer chemotherapy and pharmacology.
2013 Nov; 72(5):1043-53. doi:
10.1007/s00280-013-2282-y
. [PMID: 24043137] - Wen Zhang, Ai-Ping Zhou, Qiong Qin, Chun-Xiao Chang, Hao-Yuan Jiang, Jian-Hui Ma, Jin-Wan Wang. Famitinib in metastatic renal cell carcinoma: a single center study.
Chinese medical journal.
2013 Nov; 126(22):4277-81. doi:
NULL
. [PMID: 24238512] - Cen Xie, Jialan Zhou, Zitao Guo, Xingxing Diao, Zhiwei Gao, Dafang Zhong, Haoyuan Jiang, Lijia Zhang, Xiaoyan Chen. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.
British journal of pharmacology.
2013 Apr; 168(7):1687-706. doi:
10.1111/bph.12047
. [PMID: 23126373]